{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:07:08Z","timestamp":1795028828627,"version":"4.10.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA201309"],"award-info":[{"award-number":["R01CA201309"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human T cell leukemia virus type 1 (HTLV-1)-associated adult T cell leukemia (ATL) has a very poor prognosis with a median survival of 8\u2009months and a 4-year overall survival of 11% for acute ATL. Present treatment options are limited and there is no curative therapy for ATL. Ubiquitin ligase FBXW7 is commonly mutated or functionally inactivated in human cancers. Consistent with the notion that FBXW7 controls the degradation of many oncoproteins, loss of FBXW7 has been linked to increased drug resistance or sensitivity in cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In this study, we have characterized FBXW7 mutants previously identified in HTLV-I-infected ATL patient samples. TET-inducible ATL cells carrying wild type or mutated FBXW7 were analyzed for target degradation and for drug sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results demonstrate that mutations in FBXW7 can selectively disrupt ubiquitination and proteasome degradation of target proteins: c-MYC, cyclin E and MCL1. Both c-MYC and MYCN were highly expressed in uncultured ATL patient\u2019s samples and ATL-derived cell lines; and ATL cells demonstrated sensitivity to BET inhibitors in vitro and in vivo. High-throughput reverse phase protein array revealed BRAF as a novel target of FBXW7 and further experiments showed that mutations in FBXW7 preventing degradation of BRAF provided resistance to BET inhibitors. In contrast to R465, hot spot FBXW7 mutations at R505C retained degradation of BRAF but not NOTCH1, c-MYC, cyclin E, or MCL1. Finally, a combination therapy using BET inhibitors along with a BRAF or an ERK inhibitor prevented tumor cell resistance and growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that FBXW7 status may play an important role in drug therapy resistance of cancer cells. Genetic characterization of FBXW7 may be one factor included in future personalized cancer treatment identification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-020-01254-x","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:22:47Z","timestamp":1599722567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells"],"prefix":"10.1186","volume":"19","author":[{"given":"Chien-Hung","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-2869","authenticated-orcid":false,"given":"Christophe","family":"Nicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"issue":"4","key":"1254_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","volume":"14","author":"Z Wang","year":"2014","unstructured":"Wang Z, et al. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14(4):233\u201347.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1254_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-018-0857-2","volume":"17","author":"CH Yeh","year":"2018","unstructured":"Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17(1):115.","journal-title":"Mol Cancer"},{"issue":"4","key":"1254_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccell.2014.09.013","volume":"26","author":"RJ Davis","year":"2014","unstructured":"Davis RJ, Welcker M, Clurman BE. Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities. Cancer Cell. 2014;26(4):455\u201364.","journal-title":"Cancer Cell"},{"issue":"5","key":"1254_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neo.2015.04.005","volume":"17","author":"R Moles","year":"2015","unstructured":"Moles R, Bellon M, Nicot C. STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells. Neoplasia. 2015;17(5):449\u201362.","journal-title":"Neoplasia"},{"issue":"45","key":"1254_CR5","doi-asserted-by":"publisher","first-page":"34439","DOI":"10.1074\/jbc.M110.152306","volume":"285","author":"Y Xu","year":"2010","unstructured":"Xu Y, et al. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 2010;285(45):34439\u201346.","journal-title":"J Biol Chem"},{"issue":"7336","key":"1254_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09779","volume":"471","author":"IE Wertz","year":"2011","unstructured":"Wertz IE, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110\u20134.","journal-title":"Nature"},{"issue":"5838","key":"1254_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/294268a0","volume":"294","author":"BJ Poiesz","year":"1981","unstructured":"Poiesz BJ, et al. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature. 1981;294(5838):268\u201371.","journal-title":"Nature"},{"issue":"6","key":"1254_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79(6):2031\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8452","key":"1254_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","volume":"2","author":"A Gessain","year":"1985","unstructured":"Gessain A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407\u201310.","journal-title":"Lancet"},{"issue":"38","key":"1254_CR10","doi-asserted-by":"publisher","first-page":"16619","DOI":"10.1073\/pnas.1010722107","volume":"107","author":"J Pancewicz","year":"2010","unstructured":"Pancewicz J, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A. 2010;107(38):16619\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"1254_CR11","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1073\/pnas.1601537113","volume":"113","author":"CH Yeh","year":"2016","unstructured":"Yeh CH, et al. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A. 2016;113(24):6731\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"1254_CR12","doi-asserted-by":"crossref","first-page":"16288","DOI":"10.1016\/S0021-9258(18)41998-9","volume":"267","author":"MP Duyao","year":"1992","unstructured":"Duyao MP, et al. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem. 1992;267(23):16288\u201391.","journal-title":"J Biol Chem"},{"issue":"2","key":"1254_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/(SICI)1096-9896(1998100)186:2<209::AID-PATH162>3.0.CO;2-I","volume":"186","author":"AP Hall","year":"1998","unstructured":"Hall AP, et al. Tumours derived from HTLV-I tax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. J Pathol. 1998;186(2):209\u201314.","journal-title":"J Pathol"},{"issue":"1","key":"1254_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0014-5793(93)81101-5","volume":"322","author":"M Fujita","year":"1993","unstructured":"Fujita M, Shiku H. A human T lymphotropic virus type I (HTLV-I) long terminal repeat-directed antisense c-myc construct with an Epstein-Barr virus replicon vector inhibits cell growth in a HTLV-I-transformed human T cell line. FEBS Lett. 1993;322(1):15\u201320.","journal-title":"FEBS Lett"},{"issue":"6853","key":"1254_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/35095076","volume":"413","author":"H Strohmaier","year":"2001","unstructured":"Strohmaier H, et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001;413(6853):316\u201322.","journal-title":"Nature"},{"issue":"48","key":"1254_CR16","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1038\/sj.onc.1210518","volume":"26","author":"AC Minella","year":"2007","unstructured":"Minella AC, et al. p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene. 2007;26(48):6948\u201353.","journal-title":"Oncogene"},{"key":"1254_CR17","doi-asserted-by":"crossref","unstructured":"Moore JD. In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation? Nat Rev Cancer. 2013;13(3):201\u20138.","DOI":"10.1038\/nrc3468"},{"issue":"17","key":"1254_CR18","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/sj.onc.1204304","volume":"20","author":"R Iwanaga","year":"2001","unstructured":"Iwanaga R, et al. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 2001;20(17):2055\u201367.","journal-title":"Oncogene"},{"issue":"28","key":"1254_CR19","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1038\/sj.onc.1207648","volume":"23","author":"J Michels","year":"2004","unstructured":"Michels J, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 2004;23(28):4818\u201327.","journal-title":"Oncogene"},{"issue":"9","key":"1254_CR20","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91(9):3379\u201389.","journal-title":"Blood"},{"issue":"16","key":"1254_CR21","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood-2009-07-231050","volume":"116","author":"AY Swaims","year":"2010","unstructured":"Swaims AY, et al. Immune activation induces immortalization of HTLV-1 LTR-Tax transgenic CD4+ T cells. Blood. 2010;116(16):2994\u20133003.","journal-title":"Blood"},{"issue":"7336","key":"1254_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, et al. SCF (FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104\u20139.","journal-title":"Nature"},{"issue":"50","key":"1254_CR23","doi-asserted-by":"publisher","first-page":"36094","DOI":"10.1074\/jbc.M113.485029","volume":"288","author":"X Wu","year":"2013","unstructured":"Wu X, et al. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor kappaB (NF-kappaB) signaling. J Biol Chem. 2013;288(50):36094\u2013105.","journal-title":"J Biol Chem"},{"key":"1254_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.humpath.2018.02.003","volume":"75","author":"Y Xu","year":"2018","unstructured":"Xu Y, et al. Overexpression of BCAT1 is a prognostic marker in gastric cancer. Hum Pathol. 2018;75:41\u20136.","journal-title":"Hum Pathol"},{"issue":"7680","key":"1254_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature24294","volume":"551","author":"S Raffel","year":"2017","unstructured":"Raffel S, et al. BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 2017;551(7680):384\u20138.","journal-title":"Nature"},{"key":"1254_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-016-0500-z","volume":"15","author":"CH Yeh","year":"2016","unstructured":"Yeh CH, et al. Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. Mol Cancer. 2016;15:15.","journal-title":"Mol Cancer"},{"issue":"1","key":"1254_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2353\/ajpath.2010.090236","volume":"176","author":"H Sato","year":"2010","unstructured":"Sato H, et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia\/lymphoma. Am J Pathol. 2010;176(1):402\u201315.","journal-title":"Am J Pathol"},{"issue":"8","key":"1254_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O'Neil","year":"2007","unstructured":"O'Neil J, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813\u201324.","journal-title":"J Exp Med"},{"issue":"1","key":"1254_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17(1):164.","journal-title":"Mol Cancer"},{"issue":"1","key":"1254_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79.","journal-title":"Mol Cancer"},{"issue":"8","key":"1254_CR31","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9(8):2344\u201353.","journal-title":"Mol Cancer Ther"},{"key":"1254_CR32","doi-asserted-by":"publisher","unstructured":"Nicot C. HTLV-I Tax-Mediated Inactivation of Cell Cycle Checkpoints and DNA Repair Pathways Contribute to Cellular Transformation: \"A Random Mutagenesis Model\". J Cancer Sci. 2015;2(2). https:\/\/doi.org\/10.13188\/2377-9292.1000009.","DOI":"10.13188\/2377-9292.1000009"},{"issue":"10","key":"1254_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004458","volume":"10","author":"YB Choi","year":"2014","unstructured":"Choi YB, Harhaj EW. HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog. 2014;10(10):e1004458.","journal-title":"PLoS Pathog"},{"issue":"40","key":"1254_CR34","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz JA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1254_CR35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1084\/jem.20070872","volume":"204","author":"BJ Thompson","year":"2007","unstructured":"Thompson BJ, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204(8):1825\u201335.","journal-title":"J Exp Med"},{"issue":"8","key":"1254_CR36","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai J, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1254_CR37","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","volume":"16","author":"UA Germann","year":"2017","unstructured":"Germann UA, et al. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1\/2 Inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017;16(11):2351\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1254_CR38","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904\u201317.","journal-title":"Cell"},{"issue":"7504","key":"1254_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani IA, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278\u201382.","journal-title":"Nature"},{"issue":"7370","key":"1254_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524\u20138.","journal-title":"Nature"},{"issue":"25","key":"1254_CR41","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2012-07-439109","volume":"121","author":"M Bellon","year":"2013","unstructured":"Bellon M, et al. Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood. 2013;121(25):5045\u201354.","journal-title":"Blood"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-020-01254-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:41:55Z","timestamp":1631130115000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01254-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01254-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiments were approved by the Use Committee for Animal Care at Sun Yat-sen University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no financial conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}